Psychiatry

If existing case law and legislation is clear and well-developed, then an asset protection plan that falls within the pre-set boundaries should have favorable and predictable results.

We have been publishing MDNG for a decade now, and healthcare technology has changed in so many ways in those years.

Sermo.com CEO Daniel Palestrant recently proclaimed that the AMA no longer speaks for US physicians, and that now is the time to “turn to entities like Sermo where physicians are establishing a new voice to collectively discuss the future of our profession.”

You may have seen advertisements, or may already have been contacted by people who’ve promised to help you figure it all out so you can get your share of the stimulus money. Be wary.

Unexpected technology applications are transforming daily practice—everything from how you search for clinical information to how you share and store your data.

What do physicians really think about the HITECH act, health IT stimulus incentives, and the government’s new role in their lives? Using the power of social media, we did a little research and asked MDNG readers to share their opinions, concerns, and advice.

The FDA yesterday approved Invega Sustenna, an extended-release injectable suspension, for the acute and maintenance treatment of schizophrenia in adults.

Researcher John Csernansky, MD, is working to produce a "map of the unique dips, swells and crevasses of the brains of individuals that he hopes will provide the first scientific tool for early and more definite diagnosis of mental disorders such as schizophrenia."

Many states are seeing the HITECH money as an opportunity to aggressively promote health IT to improve healthcare through adoption of EHRs and health information exchanges.

The story of how journal editors, the clinical research community, and Big Pharma managed to work together to protect the public health, ensure the continued advance of medical science, and safeguard vital intellectual property.

We Know You Have an Opinion about This!

One nice thing about a 'psychodynamic blog' is that it can be about anything, since any issue involving humans will have a psychodynamic aspect. But when looking for a story about psychodynamics it is hard to find more content than a story about a drug addict.

Much data of note are coming to light of late regarding factors which diminish some of the ravages of aging. I posted on this recently. However, several abstracts from the ongoing Alzheimer's Association International Conference on Alzheimer's Disease, in Vienna, Austria, deserve comment.

Patients who are depressed suffer from somatoform pain more often than non-depressed patients, according to new research from scientists at the Johannes Gutenberg University Mainz.

Is there a difference between autobiographical memory and episodic memory? Are they identical, as some researchers have treated them, or is autobiographical memory “a superordinate system with episodic memory as a subsystem.”

Insulin resistance is a well-known underlying mechanism in such metabolic disorders as diabetes, hypertension, obesity, and dyslipidemia, all of which increase the risk of Alzheimer’s disease.

A poster by Daniel L. Murman, MD, University of Nebraska Medical Center, and colleagues asks a key question in this era of managed care, tightening healthcare budgets, and possible comprehensive healthcare reform: could a tool that measures the level of care needed by patients with Alzheimer’s disease be used to help evaluate the cost effectiveness of AD treatments and therapies?

The presenter discusses objective, design, and results of this study, which was undertaken to examine the long-term effect of combined pharmacologic and non-pharmacologic interventions in geriatric patients with depression, mixed dementia, and cardiovascular comorbidities.

Today’s featured resource is the Internet-based Forecasting of the Burden of Alzheimer’s Disease (iFBAD) website developed by Ron Brookmeyer, PhD, Elizabeth Colantuoni, PhD, and colleagues in the Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health.

From a pharmacologic perspective metoclopramide is much closer to antipsychotic drugs, in that it is, in part, a blocker of central dopamine receptors.

Kara M. Erwin discusses the challenges faced by Alzheimer’s disease researchers seeking to find brain donors.

The theme for the Tuesday session was “Alzheimer's disease Biomarkers: Update from the Alzheimer's Disease Neuroimaging Initiative.”

Rodrigo O. Kuljis discusses the challenges to our understanding of neurodegenerative disorders and to the development of effective treatments and prevention presented because we lack a “satisfactory, unanimously agreed and unifying conceptual scheme” for them.

The number of people with Alzheimer's and dementia – both new cases and total numbers with the disease – continues to rise among the very oldest segments of the population in contradiction of the conventional wisdom.